0 Items
Select Page

Hepatitis A

Hepatitis A is a liver disease caused by the hepatitis A virus. The virus is primarily spread when an uninfected (and unvaccinated) person ingests food or water that is contaminated with the faeces of an infected person. The spread of disease is closely linked to unsafe water and food, or inadequate sanitation and poor personal hygiene. Unlike hepatitis B and C, hepatitis A infection does not cause chronic liver disease and is rarely fatal, but can cause debilitating symptoms and fulminant hepatitis (acute liver failure), which is often fatal.

The Native Antigen Company offer a panel of monoclonal antibodies specific to the hepatitis A virus, to facilitate research and assay development.

Hepatitis A Background

Hepatitis A virus (HAV) is a non-enveloped, positive-sense, single stranded RNA virus and member of the Hepatovirus genus of the family Picornaviridae. One serotype and six genotypes, I to VI, of HAV have been defined. Genotypes I, II and III are known to infect humans and are further divided into subtypes A and B. Infection with any of these subtypes provides an individual with lifelong immunity against all HAV viruses that affect humans.

Humans are a natural reservoir for hepatitis A virus. Transmission of occurs primarily via the oral-faecal route through ingestion of HAV contaminated food and water, or through direct contact with an individual infected with HAV. In developing countries, Hepatitis A virus infection commonly occurs in children and is associated with poor sanitation and low socio-economic status. In developed countries, cases of HAV infection may occur in young adults that are in high-risk groups such as care workers, people who inject drugs and individuals travelling from HAV endemic countries.

HAV is thermostable and resistant to treatment with acids, ethers and disinfectants. The hepatitis A virus infects the liver and replicates in hepatocytes, causing liver inflammation. During the incubation stage of HAV infection, an infected individual may be asymptomatic, but virus particles are actively shed and can be present in the patient’s stools. A range of non-specific clinical symptoms may then develop, which include nausea, vomiting, joint pain, malaise, fatigue and fever. Additional symptoms that can occur include cough, pharyngitis, itchiness and hives. As the infection develops, the patient becomes jaundiced and, in some cases, hepatomegaly occurs. The mortality rate associated with HAV infection is low, but complications can lead to acute liver failure and death in a small percentage of cases. Although effective vaccines for the prevention of HAV infection are available, there is currently no specific treatment for patients infected with HAV (WHO).

References

  1. World Health Organization: Hepatitis A, key facts
  2. Hepatitis A Antibodies

Hepatitis A Antibodies

The Native Antigen company offers a range of monoclonal antibodies specific to the hepatitis A virus, offering a panel suitable for the development of immunoassays. These include a Hepatitis A antibody specific to the VP3 capsid polypeptide antigen, which has been shown to have neutralising activity.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Using Adenoviruses to Fight Cancer

In the second of a 2-part series, we discuss how adenoviruses are being developed to treat cancer and some of the hurdles these platforms face from our own immune systems. Curing cancer is one of the biggest challenges of the 21st century. Our knowledge of cancer’s...

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

In September 2018 The Native Antigen Company and Virology Research Services (VRS) were awarded the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) to test a large panel of our viral antibodies in immunofluorescence applications. This...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

11 + 10 =

Live Customer Feedback